Pancreatic cancer can now be advantageously treated by different types of cell-based immune therapy.
Our Global Cancer Navigation Service helps cancer patients access the world's most effective personalised immune therapies.
For pancreatic cancer patients, these can be combined with other appropriate high-tech treatments such as CyberKnife and Proton Beam Therapy, for improved therapeutic outcomes...
Before making any major decisions, is important to understand the significant differences between the two types of immune therapies.
- mass produced drug based immune therapies
- personalised blood & tissue-based immune therapies (made from you)
Drug based immune therapies (immunotherapy)
- Occasional outstanding outcomes.
- Works well with some melanomas.
- Severe and unpredictable side effects.
- Drug-based immune therapies cannot be personalised.
- Beneficial to less than 10% of patients.
- Still experimental – patients on medical trials.
- Some trials have been aborted due to severe, unpredictable life threatening side effects.
- Manufactured by large pharmaceutical companies – mass distributed.
- Mass production = large profits = heavily promoted.
Blood or blood tumour based immune therapies
- Personalised - made from each individual's blood or tissue.
- Provided to the patient by a series of personalised vaccines.
- Nil to low side effects – little unpredictability.
- Proven - not experimental - used in Japan since the 1990s. Over 10,000 patients have benefited.
- Creates improved survival outcomes when combined with other therapies such as – hypothermia, low-dose chemotherapy and modern high-tech targeted radiation treatments – such as proton Beam therapy, cyber knife, stereotactic radiation and more.
- Personalised – cannot be mass produced for large profit.
Despite their safety and efficacy, immune therapies and adjunct treatments produce best outcomes when meticulously coordinated and designed.
Proper timing and sequencing of treatments of these therapies is imperative.
This is the role of the cancer navigator who is like a conductor responsible for the timing (and sequencing) of the orchestra (the cancer doctors).
The skillful conductor, (cancer navigator) helps the orchestra (your team doctors) produce a musical masterpiece. (Your Health Restoration)
With meticulous timing and sequencing – your outcomes are greatly enhanced.
Before the advent of genomic diagnostic tests and pharmacogenomics, the five-year survival rate of pancreatic cancer was seven per cent, with standard therapy a "one-size-fits-all" combination chemotherapy approach.
Sadly, this is still the common (gold standard) approach in hospitals throughout Australia, NZ, UK, Canada and similar.
Our Global Cancer Navigation Service also utilises state-of-the-art tools such as genomic screening and diagnostics.
These tests can help pinpoint targeted cancer treatments with more accuracy than ever before. Pharmacogenomic tests reveal the patient's ability to metabolise treatments ensuring side-effects are minimal.
Who are we and what is our experience?
Grace Gawler Institute Global Cancer Navigation Service
The Grace Gawler Institute, works closely with our national and international oncology colleagues and networks to help patients source state-of-the-art treatments in Australia, New Zealand, UK, Canada or overseas.
We have 30 years experience referring patients overseas for treatments they could not access in their home countries.
The link below (disrupters) explains how our global cancer navigation service is disrupting outdated, unwieldy, hospital approaches to Cancer.
Collaborating with innovative leading cancer doctors around the world means we see what is possible - it provides us with a unique benchmark for what our patients deserve.
The statement, there is nothing more we can do, speaks to the limitations of that hospital, typically in countries like Australia, NZ, UK and Canada, where many of our patients come from.
The treatments we help patients access will eventually be adopted in most countries. But it may take many years. Our patients can access them now – in November 2017.
For better understanding of our new paradigm cancer services, please carefully read our website front page & associated links.
Welcome: I'm Grace Gawler, Cancer Navigator & Patient Advocate.
I've now worked with cancer patients for 43 years. As we approach 2018, I am able to help pancreatic cancer patients access the best of what is commonly called precision medicine.
(personalised or targeted medicine)
This level of precision medicine is not usually available in countries like Australia, Canada, New Zealand, UK.
With genomic screening and diagnostic tests able to pinpoint targeted treatments with higher probabilities of success, and, with high-tech treatments such as proton Beam therapy, and others, this once difficult to treat disease is no longer a death sentence.
Via my global medical alliance of innovative cancer specialists, we can provide a range of exceptional new treatments for pancreatic cancer patients.